Evidence map›Paper›PMID 41874947›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer.

Viktoria B Poluektova, Svetlana N Zuevskaya, Yarmatov Suvon, Sharipova Gulnihol, Rustam Turakulov, Feruza Umirkulova

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Viktoria B PoluektovaDepartment of Infectious Diseases, Institute of Public Health named after F.F. Erisman, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Svetlana N ZuevskayaDepartment of Infectious Diseases, Institute of Public Health named after F.F. Erisman, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. zuevskaya_s_n@outlook.com.ORCID http://orcid.org/0000-0002-2862-2456
Yarmatov SuvonDepartment of Propaedeutics of Internal Diseases, Samarkand Medical University, Samarkand, Uzbekistan.
Sharipova GulniholDepartment of Hygiene No.2, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan.
Rustam TurakulovDepartment of Internal Medicine in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan.
Feruza UmirkulovaDepartment of Medicine, Termez University of Economics and Service, Termez, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past several decades, chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer immunotherapy, particularly for hematological cancers. However, its effectiveness against solid tumors is often hindered by numerous barriers. Advances in modern epigenomic profiling technologies have deepened our understanding of how epigenetic regulation shapes CAR-T cell behavior. Epigenetic mechanisms act as an unseen force that governs CAR-T cell fate by modulating key genes involved in metabolism, differentiation, phenotype, migration, persistence, and overall function. Recent innovations in epigenetic monitoring and manipulation have provided new strategies to address the challenges that restrict CAR-T cell performance. In this review, we examine the epigenetic landscape of CAR-T cells and discuss potential epigenetic-based strategies to enhance CAR-T cell function and overcome limitations in CAR-T cell therapy. Trial registration number: not applicable.

Indexed as

Epigenesis, GeneticImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenEpigenome EditingHumansT-LymphocytesReceptors, Chimeric AntigenCAR-TEpigenome editingEpigenome profilingSolid tumorsT-lymphocyte

Identifiers

PMID41874947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.